Regeneron shares fall after skin cancer trial miss
Regeneron shares dropped 11.6% premarket after its fianlimab-cemiplimab combination failed to reach statistical significance in a late-stage trial for advanced melanoma. The setback follows previous regulatory delays and pipeline failures, increasing pressure on the company's clinical development.
Xurve View
Insights:
Xurve View
Regeneron fell 11.6% in premarket trading on Monday after its experimental melanoma treatment failed to meet the main goal in a late-stage head-to-head trial. The failure follows regulatory delays for Eylea and a late-stage miss for Regeneron's lung disease treatment itepekimab last year. Back-to-back pipeline setbacks increase pressure on Regeneron's clinical development timeline over the next 12 to 18 months.
